Search results for "Liver cirrhosis"

showing 10 items of 598 documents

Non invasive tools for the diagnosis of liver cirrhosis

2014

Liver cirrhosis (LC), the end stage of many forms of chronic hepatitis of different etiologies is a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules surrounded by annular fibrosis. This chronic progressive clinical condition, leads to liver cell failure and portal hypertension, which can favour the onset of hepatocellular carcinoma. Defining the phase of the natural history is crucial for therapeutic choice and prognosis. Liver biopsy is currently considered the best available standard of reference but it has some limits, so alternative tools have been developed to substitute liver biopsy when assessing liver fibros…

Diagnostic ImagingLiver Cirrhosismedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaBiopsyContrast MediaReviewSeverity of Illness IndexGastroenterologySerum markersPredictive Value of TestsFibrosisInternal medicineUltrasoundBiopsymedicineHumansLiver fibrosis; Liver biopsy; Ultrasound; Elastography; Serum markersmedicine.diagnostic_testbusiness.industryLiver cellGastroenterologyReproducibility of ResultsLiver fibrosiUltrasonography DopplerGeneral MedicineLiver biopsyPrognosismedicine.diseaseLiverLiver biopsyHepatocellular carcinomaElasticity Imaging TechniquesPortal hypertensionRadiologyElastographyElastographybusinessBiomarkers
researchProduct

Spontaneous rupture of umbilical hernia in end stage liver disease patient: injection of fibrin glue as a temporary solution.

2021

Background. Umbilical hernia is a common disease, which occurs in 20% of cirrhotic patients in the presence of persistent ascites. A rare but dangerous complication of this disease in end stage liver patient is a spontaneous rupture of umbilical hernia with ascitic fluid leaking. Up to date there is no general consensus on its most appropriate treatment. Case report. A 60 years-old male patient, with Child Pugh C and Meld score of 18 end stage liver disease, came to our observation for a spontaneous minimal rupture of his long lasting 5 cm umbilical hernia with ascitic fluid leaking. A medical therapy was undertaken aiming to manage the ascites and a temporary conservative therapy, with fib…

End Stage Liver DiseaseLiver CirrhosisMaleRupture SpontaneousUmbilical herniaHernioplastyAscitesHumansFibrin Tissue AdhesiveMiddle AgedFlood syndromeHernia UmbilicalLa Clinica terapeutica
researchProduct

Management of infections in cirrhotic patients: Report of a Consensus Conference

2014

a b s t r a c t The statements produced by the consensus conference on infection in end-stage liver disease promoted by the Italian Association for the Study of the Liver, are here reported. The topics of epidemiology, risk factors, diagnosis, prophylaxis, and treatment of infections in patient with compensated and decompensated liver cirrhosis were reviewed by a scientific board of experts who proposed 26 statements that were graded according to level of evidence and strength of recommen- dation, and approved by an independent jury. Each topic was explored focusing on the more relevant clinical questions. By systematic literature search of available evidence, comparison and discussion of e…

Fungal infectionLiver Cirrhosismedicine.medical_specialtyAntifungal Agentsmedia_common.quotation_subjectInfectionsGastroenterologyBacterial infection; Cirrhosis; Fungal infections; Infections; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Evidence-Based Medicine; Humans; Liver Cirrhosis; Mycoses; Hepatology; GastroenterologyLiver diseaseFungal infectionsJuryInternal medicineEpidemiologymedicineHumansIn patientGrading (education)Bacterial infection; Cirrhosis; Fungal infections; Infectionsmedia_commonCirrhosiEvidence-Based MedicineHepatologybusiness.industryConsensus conferenceGastroenterologyEvidence-based medicineBacterial Infectionsmedicine.diseaseAnti-Bacterial AgentsMycosesCirrhosisFamily medicineBacterial infectionbusinessInfectionSystematic search
researchProduct

Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid.

2015

Gadoxetic acid improves detection and characterization of focal liver lesions in cirrhotic patients and can estimate liver function in patients undergoing liver resection. The purpose of this article is to describe the optimal gadoxetic acid study protocol for the liver, the unique characteristics of gadoxetic acid, the differences between gadoxetic acid and extra-cellular gadolium chelates, and the differences in phases of enhancement between cirrhotic and normal liver using gadoxetic acid. We also discuss how to obtain and recognize an adequate hepatobiliary phase.

Gadolinium DTPALiver CirrhosisGadoxetic acidCirrhotic livermedicine.medical_specialtySettore MED/09 - Medicina InternaCirrhosisCarcinoma HepatocellularGadoxetic acidContrast MediaGastroenterology030218 nuclear medicine & medical imagingResection03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansIn patientTopic HighlightSettore MED/12 - GastroenterologiaCirrhosimedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyHepatobiliary contrast materialMagnetic resonance imagingGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingSettore MED/18 - Chirurgia GeneraleLiver030220 oncology & carcinogenesisHepatobiliary phaseLiver functionSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessCirrhosis; Gadoxetic acid; Hepatobiliary contrast materials; Liver; Magnetic resonance imaging; Gastroenterologymedicine.drugWorld journal of gastroenterology
researchProduct

MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.

2016

Purpose: The purpose of the study is to compare the MR-imaging features of hepatocellular carcinoma (HCC) capsule appearance on gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, using imaging-based presumptive diagnosis of HCC as the reference standard. Methods: Gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging of 51 patients with 71 HCCs were retrospectively reviewed. Three readers graded in consensus, using a five-point scale, the presence (score 4–5) of capsule appearance on images obtained during T1-weighted GRE portal venous phase (PVP), 3-min phase, and hepatobiliary phase (HBP). The Fisher's exact test and the t student unpaired test were performed. Results: …

Gadolinium DTPALiver CirrhosisMaleCirrhotic livermedicine.medical_specialtyGadoxetic acidCarcinoma HepatocellularHepatocellular carcinomaUrologyGadoxetic acidContrast MediaSensitivity and Specificity030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMeglumineInternal medicineGadobenate dimegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingGADOBENATE DIMEGLUMINECapsuleAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyCapsuleReproducibility of ResultsHepatologyHCCSMiddle Agedmedicine.diseaseImage EnhancementMr imagingMagnetic Resonance Imagingdigestive system diseasesLiver030220 oncology & carcinogenesisHepatocellular carcinomaFemaleRadiologybusinessMR imagingmedicine.drugAbdominal radiology (New York)
researchProduct

Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?

2020

Purpose: To compare the level of parenchymal and portal venous enhancement in the portal venous phase (PVP) in cirrhotic patients undergoing gadoxetate disodium- and gadobenate dimeglumine-enhanced MRI. Methods: In this retrospective study, 84 cirrhotic patients (mean age ± SD: 66 ± 13 years) who underwent contrast-enhanced MRI with both gadoxetate disodium and gadobenate dimeglumine between 2012 and 2018 were included. Two readers measured signal intensities of hepatic parenchyma, portal vein and psoas muscle on precontrast and PVP. Relative enhancement (RE), image contrast, and portal vein-to-liver contrast difference were calculated. Intraindividual differences were compared with the Wil…

Gadolinium DTPALiver Cirrhosismedicine.medical_specialtyCirrhosisUrologyPortal veinContrast MediaPortal venous phase030218 nuclear medicine & medical imagingGadoxetate Disodium03 medical and health sciences0302 clinical medicinePrecontrastMeglumineInternal medicineGadobenate dimegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingGADOBENATE DIMEGLUMINEAgedRetrospective StudiesCirrhosis Portal vein Gadobenate dimeglumine Gadoxetate disodium Hepatic parenchymaHepatic parenchymaRadiological and Ultrasound Technologybusiness.industryGastroenterologyHepatologyMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingCirrhosisHepatic parenchyma030220 oncology & carcinogenesisPortal veinGadoxetate disodiumNuclear medicinebusiness
researchProduct

TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis.

1999

Transforming growth factor-beta1 (TGF-beta1) is a powerful stimulus for collagen formation in vitro. To determine the in vivo effects of TGF-beta1 on liver fibrogenesis, we generated transgenic mice overexpressing a fusion gene [C-reactive protein (CRP)/TGF-beta1] consisting of the cDNA coding for an activated form of TGF-beta1 under the control of the regulatory elements of the inducible human CRP gene promoter. Two transgenic lines were generated with liver-specific overexpression of mature TGF-beta1. After induction of the acute phase response (15 h) with lipopolysaccharide (100 microgram ip), plasma TGF-beta1 levels reached600 ng/ml in transgenic animals, which is100 times above normal …

Genetically modified mouseLipopolysaccharidesmedicine.medical_specialtyTranscription GeneticPhysiologyTransgeneRecombinant Fusion ProteinsMice TransgenicBiologyRegulatory Sequences Nucleic AcidLiver Cirrhosis ExperimentalMiceDownregulation and upregulationFibrosisIn vivoTransforming Growth Factor betaPhysiology (medical)Internal medicinemedicineAnimalsHumansRNA MessengerPromoter Regions GeneticRegulation of gene expressionHepatologyGastroenterologymedicine.diseaseMolecular biologyImmunohistochemistryEndocrinologymedicine.anatomical_structureC-Reactive ProteinGene Expression RegulationLiverHepatocyteHepatic stellate cellCollagenProcollagen
researchProduct

Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A.

2008

Platelet derived growth factor (PDGF) plays a central role in repair mechanisms after acute and chronic tissue damage. To further evaluate the role of PDGF-A in liver fibrogenesis in vivo, we generated transgenic mice with hepatocyte-specific overexpression of PDGF-A using the CRP-gene promoter. Transgenic but not wildtype mice showed expression of PDGF-A mRNA in the liver. Hepatic PDGF-A overexpression was accompanied by a significant increase in hepatic procollagen III mRNA expression as well as TGF-beta1 expression. Liver histology showed increased deposition of extracellular matrix in transgenic but not in wildtype mice. PDGF-A-transgenic mice showed positive sinusoidal staining for alp…

Genetically modified mouseLiver CirrhosisPlatelet-derived growth factorTransgeneGene ExpressionMice TransgenicTransforming Growth Factor beta1chemistry.chemical_compoundMiceFibrosisGeneticsmedicineAnimalsHumansRNA MessengerPlatelet-Derived Growth FactorbiologyGeneral Medicinemedicine.diseaseMolecular biologyRecombinant ProteinsC-Reactive ProteinCollagen Type IIIchemistryLiverHepatic stellate cellbiology.proteinHepatic fibrosisTyrosine kinasePlatelet-derived growth factor receptorSignal TransductionGene
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in li…

2008

Introduction. Long-term steroid administration may predispose liver transplant recipients to infectious and metabolic complication. Maintaining effective immunoprophylaxis while minimizing the negative consequences of steroid therapy could be a key factor in improving clinical outcomes.Methods. Six hundred two patients were randomized to receive tacrolimus (TAC) immunosuppression with a single-steroid bolus and two doses of daclizumab (DAC) or mycophenolate mofetil (MMF).Results. The incidence of biopsy-proven acute rejection was 19.7% in the TAC/DAC group and 16.2% in the TAC/ MMF group (ns). Three-month patient and graft survival were similar. Steroid use at month-3 was low at 5.5% in the…

Graft RejectionLiver CirrhosisMaleDaclizumabmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterology0302 clinical medicineDaclizumabAdrenal Cortex HormonesSafety outcomeAntibacterial agentLiver NeoplasmsAntibodies Monoclonal3. Good healthTreatment OutcomeAcute DiseaseCorticosteroid030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classchemical and pharmacologic phenomenaAntibodies Monoclonal HumanizedMycophenolic acidTacrolimusABO Blood-Group System03 medical and health sciencesInternal medicinemedicineHumansTransplantationTacrolimus monotherapybusiness.industryPatient SelectionSteroid-free immunosuppressionMycophenolic AcidSurvival AnalysisTacrolimusSurgeryLiver TransplantationCalcineurinstomatognathic diseasesRegimenImmunoglobulin GbusinessTransplantation
researchProduct